Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Acura Pharmaceuticals Inc (NASDAQ:ACUR)

2.87
Delayed Data
As of Sep 04
 0.00 / 0.00%
Today’s Change
2.05
Today|||52-Week Range
6.75
+27.56%
Year-to-Date
SECTOR
--
INDUSTRY
--
MARKET CAP
--

Company Description

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company, which is engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary aversion and impede technologies. It operates its business through the research, development and manufacture of innovative abuse deterrent, orally administered pharmaceutical products. The company was founded in 1935 and is headquartered in Palatine, IL. Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company, which is engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary aversion and impede technologies. It operates its business through the research, development and manufacture of innovative abuse deterrent, orally administered pharmaceutical products. The company was founded in 1935 and is headquartered in Palatine, IL.

Contact Information

Acura Pharmaceuticals, Inc.
616 N. North Court
Palatine Illinois 60067
P:(847) 705-7709
Investor Relations:

Employees

Shareholders

Individual stakeholders99.35%
Other institutional17.90%
Mutual fund holders1.97%

Top Executives

Robert B. JonesPresident, Chief Executive Officer & Director
Peter A. ClemensCFO, Secretary, SVP & Head-Investor Relations
Albert W. BrzeczkoVice President-Technical Affairs
Robert A. SeiserTreasurer, Vice President & Controller
James F. EmighVice President-Corporate Development